Sangamo Therapeutics (SGMO) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$34.9 million.
- Sangamo Therapeutics' Income from Continuing Operations fell 42730.51% to -$34.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.9 million, marking a year-over-year increase of 1923.09%. This contributed to the annual value of -$97.9 million for FY2024, which is 6201.35% up from last year.
- According to the latest figures from Q3 2025, Sangamo Therapeutics' Income from Continuing Operations is -$34.9 million, which was down 42730.51% from -$20.0 million recorded in Q2 2025.
- Sangamo Therapeutics' 5-year Income from Continuing Operations high stood at $21.1 million for Q1 2023, and its period low was -$114.5 million during Q2 2023.
- Moreover, its 5-year median value for Income from Continuing Operations was -$44.0 million (2022), whereas its average is -$42.7 million.
- In the last 5 years, Sangamo Therapeutics' Income from Continuing Operations tumbled by 306326.26% in 2021 and then skyrocketed by 14800.88% in 2023.
- Sangamo Therapeutics' Income from Continuing Operations (Quarter) stood at -$37.5 million in 2021, then plummeted by 38.63% to -$51.9 million in 2022, then fell by 16.08% to -$60.3 million in 2023, then skyrocketed by 61.2% to -$23.4 million in 2024, then plummeted by 49.3% to -$34.9 million in 2025.
- Its Income from Continuing Operations was -$34.9 million in Q3 2025, compared to -$20.0 million in Q2 2025 and -$30.6 million in Q1 2025.